OKLAHOMA CITY--(BUSINESS WIRE)--ARTEC, Inc., (Pink Sheets: ATKJ), visionary pharmaceutical firm, has acquired the preliminary outline to be used for the testing protocol from a sponsoring scientific group in South Africa for TUBERCINTM, a revolutionary polysaccharide compound to be used as an HIV/AIDS and ANTI-CANCER immunostimulant.
